Immune checkpoints: A therapeutic target in triple negative breast cancer

Medicine and Dentistry

• Programmed Death-Ligand 1 100%
• Triple Negative Breast Cancer 33%
• Diseases 16%
• Combination Therapy 16%
• Non Small Cell Lung Cancer 16%
• Programmed Cell Death 16%
• Nodular Melanoma 16%
• Clear Cell Renal Cell Carcinoma 16%
• Ligand 16%
• Monoclonal Antibody 16%
• Programmed Death 1 Receptor 16%
• Inpatient 16%
• Therapeutic Procedure 16%
• T Cell 16%

INIS

• cancer 50%
• breasts 33%
• apoptosis 33%
• clinical trials 16%
• patients 16%
• diseases 16%
• kidneys 16%
• receptors 16%
• lung cells 16%
• ligands 16%
• monoclonal antibodies 16%
• melanomas 16%
• carcinomas 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Triple Negative Breast Cancer 33%
• Clinical Trial 33%
• Diseases 16%
• Ligand 16%
• Monoclonal Antibody 16%
• Non Small Cell Lung Cancer 16%
• Melanoma 16%
• Programmed Death 1 Receptor 16%